Letteratura scientifica selezionata sul tema "Byrne grant"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Byrne grant".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Byrne grant"
1
Akinto, Adetola. "Critical review of the use of financial incentives in solving health professionals' brain drain". International Journal of Research in Business and Social Science (2147- 4478) 10, n. 4 (15 giugno 2021): 446–54. http://dx.doi.org/10.20525/ijrbs.v10i4.1202.
Testo completoAbstract (sommario):
This study critically reviewed the use of financial incentives in solving health professionals’ brain drain, with the view to ascertain its effectiveness. The Systematic Assessment Quantitative Technique (SQAT) developed by Catherine Pickering and Jason Antony Byrne, was used to identify and review 21 relevant peer-reviewed journal articles that investigated six forms of financial incentives in solving health professionals’ brain drain. Evidence from 66.67% of the studies showed that financial incentives are effective in solving health professionals’ brain drain through the use of improved remuneration, funded training, return subsidy and research grant. The remaining part of the studies (33.33%) did not find the use of financial health aid and bonding effective. This study recognized that financial incentives do not fully solve healthcare brain drain and other non-financial measures need to be implemented; future research work should therefore integrate other measures with financial incentives in order to gain additional insight on solving healthcare brain drain. The use of limited but high-quality academic databases means that some articles were not considered for review.
2
Lai, Lauren, Lucia Rose, Madeline king, Henry Fraimow e Dana D. Byrne. "1262. Salvage Therapies for Carbapenem Resistant Acinetobacter baumanii Outbreak in a Tertiary Care Center". Open Forum Infectious Diseases 8, Supplement_1 (1 novembre 2021): S719—S720. http://dx.doi.org/10.1093/ofid/ofab466.1454.
Testo completoAbstract (sommario):
Abstract Background The 2019 Antimicrobial Resistance Threat Report cites carbapenem-resistant Acinetobacter baumanii (CRAB) as an urgent threat causing > 700 deaths per year.1 Acinetobacter is unique in its ability to acquire resistance determinants and pan-resistant strains have been previously reported.2 It has the propensity to cause outbreaks, especially in critically ill populations due to its ability to survive on surfaces.3,4 In 2018, our hospital experienced a large CRAB outbreak. All strains were multi-drug resistant and most were identified by the Centers for Disease Control as containing OXA-23 ß-lactamase. Standard of care (SOC) was limited to agents with high toxicity potential, and thus we explored emerging therapies. In collaboration with Shionogi Inc., we obtained compassionate use cefiderocol as salvage therapy in patients failing SOC. We present our experience utilizing various treatments for CRAB infections during a hospital outbreak. Methods We performed a retrospective chart review in adult patients with a CRAB infection treated with either cefiderocol or SOC for greater than 2 days from 08/2017 - 01/2020. SOC included use > 1 of the following: tigecycline, meropenem, polymyxins, amikacin, or eravacycline. At the time of our outbreak, we developed an institutional algorithm delineating which therapy to initiate depending on infection type. Demographic characteristics, illness severity scores, type of infection, and patient outcomes were evaluated. Results The median age [IQR] for the cefiderocol group was 57.5 [42 to 69] versus 60 [50 to 65] in the SOC group. Illness severity scores were lower in the cefiderocol group: SOFA median value [IQR] 3.5 [1.5 - 5] versus 5 [2 - 7] and CCI median value [IQR] was 3 [2.00 -3.00] versus 3 [2 -5] (Table 1). In hospital mortality was similar in both groups with the cefiderocol group having 50% in hospital mortality versus 42.2% in the SOC group. 28-day mortality was 62.6% in the cefiderocol group versus 42.4% in the SOC group (Table 2). Conclusion Cefiderocol may be a viable option for salvage therapy for CRAB infection. Our cohort illustrated similar outcomes as standard therapy. This study is limited by a small sample size receiving cefiderocol and the significant delay associated with obtaining cefiderocol at the time. Disclosures Lucia Rose, PharmD, Allergan (Speaker’s Bureau)Paratek (Employee) Madeline king, PharmD, Tetraphase (Speaker’s Bureau) Henry Fraimow, MD, Astellas pharma (Grant/Research Support)Merck (Grant/Research Support)Shionogi (Consultant, Grant/Research Support, Scientific Research Study Investigator) Dana D. Byrne, MD, MSc, Merck (Employee)
3
Nagler, Arnon, Myriam Labopin, Jan J. Cornelissen, Edouard Forcade, Patrice Chevallier, Nathalie Fegueux, Jorge Sierra et al. "Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)". Blood 138, Supplement 1 (5 novembre 2021): 3964. http://dx.doi.org/10.1182/blood-2021-144827.
Testo completoAbstract (sommario):
Abstract Background: Achieving a first complete remission (CR1) is an important prognostic factor for transplantation outcome. However, there are no data in the setting of cord blood transplantation (CBT) indicating whether the number of induction courses (1 or 2) needed to achieve CR1, is of prognostic significance. As CBT is advantageous for acute myelogenous leukemia (AML) patients (pts) with positive pre transplant measurable residual disease (MRD) (Milano F, NEJM 2016), it is conceivable that in the CBT setting, no difference in transplantation outcome will be observed between pts achieving CR1 after 1 or 2 inductions. Methods: Using the European Society for Blood and Marrow Transplantation (EBMT)/Acute Leukemia Working Party (ALWP) registry, we compared transplantation outcomes of adult pts aged ≥18 years with AML that underwent CBT in 2005-2020 in CR1, achieved following 1 versus (vs) 2 induction courses. Multivariate analysis (MVA) adjusting for differences between the induction groups was performed using a Cox's proportional-hazards regression model for main outcomes. Results: Three hundred and twenty-five pts were included comprising 243 (75%) with 1 and 82 (25%) with 2 induction chemotherapy courses. Median (range) follow-up was 65.4 (57.4-73.5) and 51.0 (34.8-61.5) months, respectively (p=0.6). Median age was 49.4 (19.0-70.9) and 52.1 (19.2-71.5) years (p=0.8), respectively. For patients with 1 and 2 induction courses, respectively, 49.4% and 57.3% were male, 225 (92.6%) and 78 (95.1%) pts had de novo AML, and 18 (7.4%) and 4 (4.9%) had secondary AML (p=0.6). Pts with 1 and 2 induction courses, respectively, were classified by cytogenetic risk as follows: intermediate, 62.0% and 79.2%, adverse, 33.2% and 19.5%, and favorable, 4.8% and 1.3% (p=0.02) (missing data~25%). The FLT3-ITD mutation was harbored by 33.7% and 32.3% of the pts (p=0.8), respectively (missing data ~6%). Conditioning was myeloablative (MAC) in 43.0% and 36.6% and reduced intensity (RIC) in 57.0% and 63.4%, respectively (p=0.31). Karnofsky performance score (KPS) was > 90 in 74.7% and 71% of the pts, respectively (p=0.5). The most frequent anti-graft-versus-host disease (GVHD) prophylaxis was cyclosporin A (CSA) and mycophenolate mofetil (MMF) in 75.6% and 82.5 %, or CSA with or without steroids in 16.1 % and 11.2%, respectively. Anti-thymocyte globulin (ATG) was administered to 32.9% and 25.6% of the CBT recipients, respectively (p=0.2). Engraftment rates were lower for pts achieving CR1 after 1 vs 2 induction courses (91.3% and 98.8% p=0.02) with corresponding day 60 absolute neutrophil count (ANC) > 0.5 x 10 9/L in 89.6% vs 96.3% of the pts (p=0.03). Day 180 incidence of acute GVHD grades II-IV was similar in both induction groups, 38.3% and 37.2% (p=0.8), as was 2-year total chronic GVHD, 23.4% and 27.5 %, respectively (p=0.6). In univariate analysis, the 2--year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were similar between patients achieving CR1 with 1 vs 2 induction courses with 22.6% vs 23.6% (p=0.87) 25.1% vs 30.4% (p=0.4), 52.3% vs 46.0% (p=0.3), 58.6% vs 50.0% (p=0.2), and 44% vs 44.1% (p=0.66), respectively. Similarly in MVA, there was no significant association between 2 courses of induction and NRM (hazard ratio (HR) = 1.1; 95% CI, 0.6-1.8, p=0.7), RI (HR = 1.4; 95% CI, 0.9-2.3, p=0.1), LFS (HR = 1.3; 95% CI, 0.9-1.8, p=0.2), OS (HR = 1.3; 95% CI, 0.9-1.9, p=0.1), and GRFS (HR = 1.1; 95% CI, 0.8-1.5, p=0.5). Conclusions: In CBT recipients, we did not find any significant differences in outcomes in patients achieving CR1 after one or two induction courses. Notably, engraftment was better in patients receiving two courses of induction chemotherapy. Figure 1 Figure 1. Disclosures Labopin: Jazz Pharmaceuticals: Honoraria. Forcade: Novartis: Other: travel grant. Sierra: Amgen: Other: Educational grant; Roche: Other: Educational grant; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alexion: Other: Educational grant; Jazz Pharmaceuticals: Research Funding; Janssen: Other: Educational grant; Novartis: Honoraria, Research Funding, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Honoraria; BMS Celgene: Honoraria, Research Funding. Byrne: Incyte: Honoraria. Blaise: Jazz Pharmaceuticals: Honoraria. Mohty: Sanofi: Honoraria, Research Funding; Pfizer: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Jazz: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Gilead: Honoraria; Celgene: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria; Astellas: Honoraria; Amgen: Honoraria; Adaptive Biotechnologies: Honoraria.
4
Ghalandari, N., M. Immink, E. Röder, P. Bruijning-Verhagen, H. T. Smeele, H. J. M. J. Crijns, N. Van der Maas, M. Bekker, L. Sanders e R. Dolhain. "AB0420 MATERNAL AND NEONATAL ANTIBODY LEVELS UPON PERTUSSIS VACCINATION IN PREGNANT WOMEN ON IMMUNE-MODULATING THERAPY FOR RHEUMATIC DISEASE". Annals of the Rheumatic Diseases 82, Suppl 1 (30 maggio 2023): 1398.1–1398. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1297.
Testo completoAbstract (sommario):
BackgroundWhile protection against pertussis following maternal tetanus-diphtheria-and-acellular-pertussis (Tdap) vaccination has been demonstrated in term-born infants from healthy mothers[1], no evidence is available on Tdap vaccination in combination with immune-modulating therapy during pregnancy.ObjectivesIn this pilot-study, we explored whether treatment with Tumor Necrosis Factor alpha inhibitors (TNFis) in pregnant patients with rheumatic disease interferes with Tdap vaccine responses and/or affects maternal IgG antibody concentrations against the relevant antigens in the newborns.MethodsPatients included by a rheumatologist during pregnancy received a Tdap vaccination in their late-second or early-third trimester. Blood samples were drawn during the first trimester, three months after delivery and from the umbilical cord. IgG antibody levels against Tdap-included antigens were measured using a bead-based multiplex immunoassay. Findings on patients exposed to TNFis were compared with those from TNFi-unexposed patients and with data from a historical comparator study among healthy Tdap vaccinated mother-infant-pairs (n=53). [2]Results66 patients (46 exposed and 20 unexposed to TNFIs) were enrolled. No differences in IgG antibody levels against Tdap-included antigens were observed between TNFi-exposed and unexposed patients before and after Tdap vaccination (Figure 1). In cord sera however, antibody levels against pertussis toxin were significantly lower after TNFi-treatment (35.94IU/mL, 95%CI 20.68-62.45) compared with no TNFis (94.61IU/mL, 95%CI 48.89-183.07) and with cord blood from the comparison cohort of healthy women-infant-pairs (125.12IU/mL, 95%CI 90.75-172.50). We observed similar differences for filamentous hemagglutinin, pertactin, tetanus toxoid, and diphtheria toxoid.ConclusionThese preliminary data indicate no reduced IgG antibody response upon maternal Tdap vaccination in pregnant women following immune-modulating treatment, although our findings suggest that TNFis during pregnancy induce lower maternal antibody levels against Tdap-included antigens in newborns.References[1] Byrne L, Campbell H, Andrews N, Ribeiro S, Amirthalingam G. Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England. Arch Dis Child. 2018;103(3):224-9.[2] Barug D, Pronk I, van Houten MA, Versteegh FGA, Knol MJ, van de Kassteele J, et al. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis. 2019;19(4):392-401.Figure 1.Anti-Pertussis toxin (anti-PT IgG) concentrations (IU/mL) before and after vaccination and in cord sera, represented for women exposed or unexposed to TNFis, or healthy pregnant women, including their offspring. X-axis: type and time-point of blood sample draw. Y-axis: IgG antibody concentration against pertussis toxin (IU/mL). Significance *p<0.05, **p<0.01, ***p<0.001.Acknowledgements:NIL.Disclosure of InterestsNafise Ghalandari Grant/research support from: Financial support for printing PhD book from UCB Pharma., Employee of: From June 2022 till February 2023 worked as a medical science liaison (MSL) at UCB Pharma., Maarten Immink: None declared, Esther Röder: None declared, Patricia Bruijning-Verhagen: None declared, Hieronymus TW Smeele: None declared, Hubertina Johanna Maria Josephina Crijns: None declared, Nicoline van der Maas: None declared, Mireille Bekker: None declared, Lieke Sanders: None declared, Radboud Dolhain Speakers bureau: from AbbVie, AstraZeneca, Eli Lily, Galapagos, Novartis, Roche, UCB., Grant/research support from: an unrestricted grant from Galapagos, UCB Pharma B.V.
5
László, Szabolcs. "“They Were All Looking West”: Robert F. Byrnes’s Travel Report on Hungary in 1962". Hungarian Studies Review 49, n. 2 (1 dicembre 2022): 224–50. http://dx.doi.org/10.5325/hungarianstud.49.2.0224.
Testo completoAbstract (sommario):
Abstract The primary source published here provides a rare and detailed account of a trip to state socialist Hungary in 1962, written by an American historian and expert on the Soviet Bloc, Robert F. Byrnes (1917–97). The document is prefaced by a short introduction that gives a brief presentation of Byrnes’s career and contextualizes his visit to Hungary as the representative of the Inter-University Committee on Travel Grants.
6
Nagra, D., K. Bechman, M. Russell, E. Alveyn, C. Baldwin, G. Bird, S. Steer et al. "AB0442 RETROSPECTIVE ANALYSIS ON JAK INHIBITORS AT SINGLE CENTRE IN THE UK". Annals of the Rheumatic Diseases 82, Suppl 1 (30 maggio 2023): 1409.2–1410. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2535.
Testo completoAbstract (sommario):
BackgroundThere are limited real world data on the use of JAK inhibitors (JAKi). In 2022, the EMA suggested that JAKi should only be used if alternative therapies are not available in patients over 65 years, smokers or in those with cardiovascular or cancer risk factors.ObjectivesWe conducted a retrospective study to describe the demographics, duration of therapy and adverse events profile of patients prescribed JAKi.MethodsBaseline data including age, gender, smoking status, ethnicity, co-morbidities, cardiovascular risk factors, rheumatic diagnosis, concomitant csDMARD use and prior biological therapies was collected. Duration on therapy and reasons for stopping JAKi were identified. A Cox proportional hazard model was used to plot survival of drug therapy, by JAKi drug. Data was analysed on the STATA platform.ResultsIn total, 151 patients were prescribed a JAKi since 2017. The average age was 55, with a female predominance, (n=125, 83%), and the majority had rheumatoid arthritis. Baricitinib and Filgotinib represented the most commonly prescribed JAKi. Over ¼ of the cohort were using JAKi monotherapy (28%). For those on combination therapy, methotrexate was the most commonly prescribed (53%). The median number of prior biologics was 1 (IQR 1-2), with TNFi the most frequently prescribed (66%). 48% had cardiovascular risk factors or cardiovascular disease; this was more prevalent in patients prescribed baricitinib or tofacitinib compared to upadacitinib or filgotinib (57%) versus (39%). During JAKi therapy 3 patients developed cancer, 2 had VTEs (both on Baricitinib) and 5 had new mental health diagnoses. The reason for stopping therapy was equally spilt between drug failure (46%) and adverse events (45%). Drug survival over 2 years was numerically higher for Filgotinib and Upadacitinib. Cycling between JAKi occurred in 28 patients. Patients prescribed a second JAKi (n=26) or a third JAKi (n=2) had cycled through more prior biologics than patients prescribed their first JAKi [median number prior biologics 2 (IQR 1-3) versus 1 (IQR 1-2) p=0.007].ConclusionOur real world experience of JAKi is broadly similar to expectations from clinical trials. The differences in patient characteristics and drug survival between individual JAKi are likely to reflect drug availability and emergence of safety warnings over time.Table 1.TotalBaricitinibFilgotinibTofacitinibUpadacitinibN=151N=43N=43N=32N=33P valueAge, (median, SD)55 (14)54 (16)57 (13)58 (11)51 (13)0.10Gender, female (n,%)125 (82.8%)36 (83.7%)37 (86.0%)28 (87.5%)24 (72.7%)0.36Smoking status, (n, %)Ex-smoker9 (6.0%)3 (7.0%)3 (7.0%)1 (3.1%)2 (6.2%)0.36Current Smoker8 (5.3%)4 (9.3%)03 (9.4%)1 (3.1%)0.46Ethnicity, (n, %)White69 (47.3%)24 (58.5%)18 (41.9%)14 (46.7%)13 (40.6%)0.25Black28 (19.2%)7 (17.1%)9 (20.9%)9 (30.0%)3 (9.4%)South Asian26 (17.8%)5 (12.2%)7 (16.3%)5 (16.7%)9 (28.1%)Mixed23 (15.8%)5 (12.2%)9 (20.9%)2 (6.7%)7 (21.9%)Diagnosis, (n,%)RA146 (96.7%)42 (97.7%)43 (100.0%)30 (93.8%)31 (93.9%)0.27Other - PsA3 (2.0%)001 (3.1%)2 (6.1%)Ank Spon1 (0.7%)001 (3.1%)0CTD overlap1 (0.7%)1 (2.3%)000Year JAK commenced20172017202120172019<0.001CVS risk factor/diseaseex/current smoker, DM, Chol73 (48.3%)25 (58.1%)21 (48.8%)18 (56.2%)9 (27.3%)0.04Prior JAK comorbidityVTE4 (2.6%)02 (4.7%)2 (6.2%)1 (3.0)0.23Cancer9 (6.0%)4 (9.3%)1 (2.3%)1 (3.1%)3 (9.1%)0.41Mental health33 (21.9%)7 (16.3%)11 (25.6%)8 (25.0%)7 (21.2%)0.72Post JAK new comorbidityCholesterol11 (7.3%)4 (9.3%)03 (9.4%)4 (12.1%)0.17Diabetes3 (2.0%)2 (4.7%)001 (3.0%)0.35IHD1 (0.7%)1 (2.3%)0000.47VTE2 (1.3%)002 (6.2%)00.06Cancer3 (2.0%)1 (2.3%)02 (6.2%)00.21Mental health5 (3.3%)1 (2.3%)1 (2.3%)03 (9.1%)0.19JAKi therapy stopped56 (37.0%)25 (58.1%)3 (6.9%)20 (62.5%)8 (24.2%)<0.001Reason for stoppingAE25 (44.6%)7 (28.0%)1 (33.3%)15 (75.0%)2 (25.0%)0.028Primary failure14 (25.0%)7 (28.0%)1 (33.3%)2 (10.0%)4 (50.0%)Secondary failure12 (21.4%)8 (32.0%)0 (0.0%)2 (10.0%)2 (25.0%)Death2 (3.6%)1 (4.0%)1 (33.3%)0 (0.0%)0 (0.0%)Not documented3 (5.4%)2 (8.0%)0 (0.0%)1 (5.0%)0 (0.0%)Figure 1.REFERENCES:NIL.Acknowledgements:NIL.Disclosure of InterestsDeepak Nagra Consultant of: Fees from abbvie, Katie Bechman Grant/research support from: Versus Arthritis and NIHR, Mark Russell Speakers bureau: Lilly, Galapagos, Biogen and Menarini, and support.for attending meetings from Lilly, Pfizer, Janssen and UCB, Consultant of: lilly, Edward Alveyn: None declared, christopher baldwin: None declared, georgina bird: None declared, Sophia Steer: None declared, Corrine Byrne: None declared, Kirsty Lawan: None declared, valeria vescovi: None declared, maryam adas Consultant of: Abbvie, Meryem Nursoy: None declared, Sam Norton Speakers bureau: janssen and pfizer, Arti Mahto Speakers bureau: Speaker fees galapagos, abbvie, GE, Andrew Rutherford: None declared, James Galloway Speakers bureau: Abbvie, Biovitrum, BMS, Celgene, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi,Sobi and UCB, Consultant of: Abbvie, Biovitrum, BMS, Celgene, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi,Sobi and UCB, Elena Nikiphorou Speakers bureau: celltrion, pfizer, sanofi, gillead, galapagos, abbvie, lilly, fresenius, Grant/research support from: pfizer and lilly.
7
KITLV, Redactie. "Book Reviews". New West Indian Guide / Nieuwe West-Indische Gids 70, n. 3-4 (1 gennaio 1996): 309–81. http://dx.doi.org/10.1163/13822373-90002626.
Testo completoAbstract (sommario):
-Bridget Brereton, Emilia Viotti Da Costa, Crowns of glory, tears of blood: The Demerara slave rebellion of 1823. New York: Oxford University Press, 1994. xix + 378 pp.-Grant D. Jones, Assad Shoman, 13 Chapters of a history of Belize. Belize city: Angelus, 1994. xviii + 344 pp.-Donald Wood, K.O. Laurence, Tobago in wartime 1793-1815. Kingston: The Press, University of the West Indies, 1995. viii + 280 pp.-Trevor Burnard, Howard A. Fergus, Montserrat: History of a Caribbean colony. London: Macmillan Caribbean, 1994. x + 294 pp.-John L. Offner, Joseph Smith, The Spanish-American War: Conflict in the Caribbean and the Pacific, 1895-1902. London: Longman, 1994. ix + 262 pp.-Louis Allaire, John M. Weeks ,Ancient Caribbean. New York: Garland, 1994. lxxi + 325 pp., Peter J. Ferbel (eds)-Aaron Segal, Hilbourne A. Watson, The Caribbean in the global political economy. Boulder CO: Lynne Rienner, 1994. ix + 261 pp.-Aaron Segal, Anthony P. Maingot, The United States and the Caribbean. London: Macmillan Caribbean, 1994. xi + 260 pp.-Bill Maurer, Helen I. Safa, The myth of the male breadwinner: Women and industrialization in the Caribbean. Boulder CO: Westview, 1995. xvi + 208 pp.-Peter Meel, Edward M. Dew, The trouble in Suriname, 1975-1993. Westport CT: Praeger, 1994. xv + 243 pp.-Henry Wells, Jorge Heine, The last Cacique: Leadership and politics in a Puerto Rican city. Pittsburgh PA: University of Pittsburgh Press, 1993. ix + 310 pp.-Susan Eckstein, Jorge F. Pérez-López, Cuba at a crossroads: Politics and economics after the fourth party congress. Gainesville: University Press of Florida, 1994. xviii + 282 pp.-David A.B. Murray, Marvin Leiner, Sexual politics in Cuba: Machismo, homosexuality, and AIDS. Boulder CO: Westview, 1994. xv + 184 pp.-Kevin A. Yelvington, Selwyn Ryan ,Sharks and sardines: Blacks in business in Trinidad and Tobago. St. Augustine, Trinidad: Institute of social and economic studies, University of the West Indies, 1992. xiv + 217 pp., Lou Anne Barclay (eds)-Catherine Levesque, Allison Blakely, Blacks in the Dutch world: The evolution of racial imagery in a modern society. Bloomington: Indiana University Press, 1993. xix + 327 pp.-Dennis J. Gayle, Frank Fonda Taylor, 'To hell with paradise': A history of the Jamaican tourist industry. Pittsburgh: University of Pittsburgh Press, 1993. ix + 239 pp.-John P. Homiak, Frank Jan van Dijk, Jahmaica: Rastafari and Jamaican society, 1930-1990. Utrecht: ISOR, 1993. 483 pp.-Peter Mason, Arthur MacGregor, Sir Hans Sloane: Collector, scientist, antiquary, founding Father of the British Museum. London: British Museum Press, 1994.-Philip Morgan, James Walvin, The life and times of Henry Clarke of Jamaica, 1828-1907. London: Frank Cass, 1994. xvi + 155 pp.-Werner Zips, E. Kofi Agorsah, Maroon heritage: Archaeological, ethnographic and historical perspectives. Kingston: Canoe Press, 1994. xx + 210 pp.-Michael Hoenisch, Werner Zips, Schwarze Rebellen: Afrikanisch-karibischer Freiheitskampf in Jamaica. Vienna Promedia, 1993. 301 pp.-Elizabeth McAlister, Paul Farmer, The uses of Haiti. Monroe ME: Common Courage Press, 1994. 432 pp.-Robert Lawless, James Ridgeway, The Haiti files: Decoding the crisis. Washington DC: Essential Books, 1994. 243 pp.-Bernadette Cailler, Michael Dash, Edouard Glissant. Cambridge: Cambridge University Press, 1995. xii + 202 pp.-Peter Hulme, Veronica Marie Gregg, Jean Rhys's historical imagination: Reading and writing the Creole. Chapel Hill: University of North Carolina Press, 1995. xi + 228 pp.-Silvia Kouwenberg, Francis Byrne ,Focus and grammatical relations in Creole languages. Amsterdam/Philadelphia: John Benjamins, 1993. xvi + 329 pp., Donald Winford (eds)-John H. McWhorter, Ingo Plag, Sentential complementation in Sranan: On the formation of an English-based Creole language. Tübingen: Max Niemeyer, 1993. ix + 174 pp.-Percy C. Hintzen, Madan M. Gopal, Politics, race, and youth in Guyana. San Francisco: Mellen Research University Press, 1992. xvi + 289 pp.-W.C.J. Koot, Hans van Hulst ,Pan i rèspèt: Criminaliteit van geïmmigreerde Curacaose jongeren. Utrecht: OKU. 1994. 226 pp., Jeanette Bos (eds)-Han Jordaan, Cornelis Ch. Goslinga, Een zweem van weemoed: Verhalen uit de Antilliaanse slaventijd. Curacao: Caribbean Publishing, 1993. 175 pp.-Han Jordaan, Ingvar Kristensen, Plantage Savonet: Verleden en toekomst. Curacao: STINAPA, 1993, 73 pp.-Gerrit Noort, Hesdie Stuart Zamuel, Johannes King: Profeet en apostel in het Surinaamse bosland. Zoetermeer: Boekencentrum, 1994. vi + 241 pp.
8
Grossniklaus, Hans E. "Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Grant MB,∗∗Program in Stem Cell Biology, Department of Pharmacology and Therapeutics, University of Florida Shands Cancer Center, Gainesville, FL 32610-0232. E-mail: grantma@pharmacology.ufl.edu May WS, Caballero S, Brown GAJ, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW. Nat Med 2002;6:607-612." American Journal of Ophthalmology 134, n. 4 (ottobre 2002): 640. http://dx.doi.org/10.1016/s0002-9394(02)01714-2.
Testo completo
9
Koslicki, Wendy. "SWAT mobilization trends: testing assumptions of police militarization". Policing: An International Journal of Police Strategies & Management 40, n. 4 (20 novembre 2017): 733–47. http://dx.doi.org/10.1108/pijpsm-08-2016-0136.
Testo completoAbstract (sommario):
Purpose The purpose of this paper is to empirically test common explanations for the growth of police militarization and to determine whether federal funding, such as Byrne grants, had a significant effect on the growth and normalization of SWAT teams. Design/methodology/approach Drawing from data spanning the years 1986-1998, an interrupted time series analysis is used to assess whether federal funding has a significant influence on the growth of SWAT teams and their mobilization for narcotics grants. Findings The findings of this analysis suggest that, at the time where federal funding was at its peak (the year 1990), there was a significant decrease in SWAT team creation compared to the years prior. There was likewise a significant decrease in SWAT mobilization for narcotics warrant in the years following 1990. Research limitations/implications The main limitation of this study is that unmeasured exogenous factors in the year 1990 may have influenced militarization trends. However, given the counterintuitive findings of this study, it is essential that more nuanced research is conducted regarding police militarization to gain a clearer understanding of trends in police culture. As this study finds that militarization is not significantly driven by federal funding, future research must incorporate other factors to explain police organizational change. Originality/value This paper provides an advanced empirical analysis that is one of the first to directly test commonly held explanations for police militarization. This analysis adds complexity to the issue of US police militarization and demonstrates that further research is essential in this area.
10
Murray, Rebecca K., e Dawn M. Irlbeck. "Evolution of the researcher–practitioner partner model and the role of academic research partners in Byrne Criminal Justice Innovation (BCJI) Grants". Contemporary Justice Review 23, n. 1 (5 dicembre 2019): 44–64. http://dx.doi.org/10.1080/10282580.2019.1700366.
Testo completoTesi sul tema "Byrne grant"
1
Senate, University of Arizona Faculty. "Faculty Senate Minutes December 2, 2013". University of Arizona Faculty Senate (Tucson, AZ), 2014. http://hdl.handle.net/10150/312042.
Testo completoLibri sul tema "Byrne grant"
1
United States. Bureau of Justice Assistance, a cura di. FY 1998 Byrne Evaluation Partnership Program. [Washington, DC]: U.S. Dept. of Justice, Office of Justice Programs, Bureau of Justice Assistance, 1998.
Cerca il testo completo
2
Peter, Haynes, Saiger Aaron J e National Institute of Justice (U.S.), a cura di. National Assessment of the Byrne Formula Grant Program. [Washington, D.C.]: U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 1997.
Cerca il testo completo
3
United States. Bureau of Justice Assistance, a cura di. Byrne Formula Grant Program guidance and instructions for application. [Washington, D.C.?]: Bureau of Justice Assistance, 1997.
Cerca il testo completo
4
Nevada. Office of Criminal Justice Assistance., a cura di. State of Nevada 2000-2002 state strategy for the Edward Byrne Memorial formula grant. Carson City, Nev: Dept of Motor Vehicles & Public Safety, Office of Criminal Justice Assistance, 2000.
Cerca il testo completo
5
Office, General Accounting. Justice discretionary grants: Byrne program and Violence Against Women Office grant monitoring should be better documented : report to congressional requesters. Washington, D.C: The Office, 2001.
Cerca il testo completo
6
Nevada. Office of Criminal Justice Assistance. State of Nevada 1996 strategy for the Edward Byrne Memorial State and Local Law Enforcement Formula Grant. Carson City, Nev: The Office, 1996.
Cerca il testo completo
7
Colorado. Division of Criminal Justice. 2004 Colorado state strategy: Edward Byrne Memorial State and Local Law Enforcement Assistance Program. Denver, Colo.]: Division of Criminal Justice, Colorado Dept. of Public Safety, 2004.
Cerca il testo completo
8
United States. Bureau of Justice Assistance, a cura di. The Edward Byrne Memorial State and Local Law Enforcement Assistance Programs: FY 1991 formula grant program guidance and application kit. Washington, D.C. (633 Indiana Ave., N.W., Washington 20531): The Bureau, 1991.
Cerca il testo completo
9
United States. Congress. House. Committee on Government Operations. Information, Justice, Transportation, and Agriculture Subcommittee. Federal assistance to state and local law enforcement: The proposed elimination of the Byrne block grant : hearing before the Information, Justice, Transportation, and Agriculture Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Third Congress, second session, March 2, 1994. Washington: U.S. G.P.O., 1994.
Cerca il testo completo
10
United, States Congress House Committee on Government Reform Subcommittee on Criminal Justice Drug Policy and Human Resources. Fiscal year 2006 drug control budget and the Byrne Grant, HIDTA, and other law enforcement programs: Are we jeopardizing federal, state, and local cooperation? : hearing before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources of the Committee on Government Reform, House of Representatives, One Hundred Ninth Congress, first session, March 10, 2005. Washington: U.S. G.P.O., 2005.
Cerca il testo completoCapitoli di libri sul tema "Byrne grant"
1
Varano, Sean, e Stephanie Manzi. "Byrne Criminal Justice Innovation Grant Program in Providence, Rhode Island". In Innovations in Community-Based Crime Prevention, 139–62. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-43635-3_7.
Testo completo
2
Slocum, Lee Ann, Cherrell Green e Thomas Owen Baker. "Unfamiliar Waters: Expectations Versus Reality for a Newly Minted Byrne Criminal Justice Innovation Grant Research Partner in the City of St. Louis". In Innovations in Community-Based Crime Prevention, 195–217. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-43635-3_9.
Testo completo
3
Blaise, Didier, e Sabine Fürst. "Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma". In The EBMT/EHA CAR-T Cell Handbook, 169–71. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_33.
Testo completoAbstract (sommario):
AbstractEven after a decade of use, CAR-T cell therapy for non-Hodgkin lymphoma (NHL) is still evolving, and disease control is now the main concern in the majority of experienced centres. Indeed, despite highly appealing objective response (OR) rates in refractory patients, the long-term overall survival (OS) of this population has only slightly improved. Pivotal studies have suggested that 2-year OS rates do not surpass 30%, even though results improve when complete response (CR) is achieved within the first 3 months after treatment (Wang et al. 2020; Schuster et al. 2019; Neelapu et al. 2017). Although achieving this exceptionally high level of OR is praiseworthy, similar improvements have not been made regarding OS, and current OS probabilities are not satisfactory. Of course, there are multiple reasons for this; a substantial proportion of patients either do not achieve an initial response or experience progression very soon after treatment, with poor OS (Chow et al. 2019). Both populations present with disease burden or aggressive cancer prior to CAR-T cell therapy, possibly having been referred too late in the course of treatment or waited too long before CAR-T cells were processed for them. Both of these issues have potential solutions, such as more widely publicizing the efficacy of CAR-T cells, which may increase referrals at an earlier stage, and developing methods, which are already being heavily investigated, for shortening the manufacturing process (Rafiq et al. 2020). In the latter case, the use of allogeneic lymphocytes could allow for already prepared cells to be readily used when needed and would most likely be the most efficient strategy as long as the risk of graft-versus host disease is offset (Graham and Jozwik 2018). Thus, achieving CR is a crucial step in increasing OS, as patients with partial response (PR) or stable disease (SD) present with lower OS, while currently, recurrence appears to be rare when CR is maintained for more than 6 months (Komanduri 2021). However, the disease will likely recur in more than half of patients in the months following treatment, possibly due to issues such as the poor persistence of CAR-T cells (which may not be as crucial as once thought for acute lymphoblastic leukaemia (Komanduri 2021)) or the loss of target antigen expression (which has been regularly documented (Rafiq et al. 2020)). Both of these mechanisms could potentially be used to develop methods that reduce recurrence after CAR-T cell therapy. In fact, the most popular approaches currently being investigated are attempting to either use two CAR-T cell types that each target different antigens or to create CAR-T cell constructs that target either multiple antigens or an antigen other than CD19 (Shah et al. 2020). The concomitant infusion of CAR-T cells with targeted therapies is also being explored in other B-cell malignancies and appears to both increase the CR rate and decrease recurrence (Gauthier et al. 2020). When recurrence does occur, patient OS is rather dismal, and the best remaining option would most likely be inclusion in a clinical trial. If this option is not available, salvage therapy may be attempted, although cytotoxic treatments are extremely limited given that most diseases have been refractory to numerous lines of treatment prior to immunotherapy. A few case reports and studies with a small patient population receiving anti-PD-1 antibodies, ibrutinib, or ImiDs have been reported with largely anecdotal supporting evidence (Byrne et al. 2019). However, even in the case of a new objective response (OR), the subsequent risk of recurrence is substantial and may invite further consolidation with allogeneic haematopoietic stem cell transplantation (Byrne et al. 2019), which has already been performed in patients treated for acute lymphoblastic leukaemia (Hay et al. 2019). However, the efficacy of this strategy remains to be validated in NHL patients in clinical trials. Further supporting evidence, although limited, has recently been reported concerning an additional treatment with CAR-T cells inducing an OR. Of the 21 NHL patients included in the study, the OR rate after the second infusion was 52% (CR, n = 4; PR, n = 7), with some durable responses inviting further investigations (Gauthier et al. 2021). Overall, with such poor outcomes after recurrence, current efforts are also focused on predicting the patients most likely to experience disease progression and that are potential candidates for preemptive consolidation therapy, although there is no doubt that patients who do not achieve a rapid CR should be the first candidates. Additionally, immune monitoring should encompass not only CAR-T cell survival but also the detection of circulating tumour DNA (Komanduri 2021) because this could aid in detecting subclinical recurrence and in deciding whether consolidation or maintenance therapy should be administered. However, currently, all these approaches are highly speculative and require further clinical study.
4
Teige, Ola. "Norske provinsmatadorer: familien Adeler og makten i Kragerø ca. 1620–1760". In Hvem styrte byene? Nordisk byhistorie 1500–1800, 245–72. Cappelen Damm Akademisk/NOASP, 2022. http://dx.doi.org/10.23865/noasp.149.ch9.
Testo completoAbstract (sommario):
Norwegian provincial matadors. The Adeler family and the power in the town Kragerø c. 1620–1760 This chapter describes the Norwegian coastal town of Kragerø and the position of the Adeler family in its political, social and commercial life in the period 1620–1760. It illustrates how local elite families exercised power in such towns in the early modern period, the strategies they used, and the sources of this power. In this regard, Kragerø is close to an ideal example of a town controlled by just one or a few mighty families. For 35 years, it was ruled by a single, undisputed “matador” and for the following 65 years by a small local elite. In the early 17th century, Kragerø developed as a shipping port for timber products from nearby sawmills. The Adeler family established themselves as sawmill owners, helped by their ties to noble county governors. The first known family member, Søren Jensen, came to the area as a servant to one of these governors. His son, Niels Adeler, inherited his father’s business and expanded it by aggressively acquiring local sawmills, forest properties and shipping businesses. This was fueled by massive lending. Adeler played a leading role when the local merchants successfully petitioned the Danish-Norwegian king to grant the port town rights in 1666. Adeler was then appointed mayor. He was both a royal official and a merchant, and in the 1670s and 80s his family controlled three-quarters of the local trade economy, i.e., ships, import of goods, and sawmills with export quotas. He also controlled the other town offices by using his network and influence with the king to install clients in them. The only power base he did not control was the land the town was built on, which was leased to the houseowners. In similar towns, this asset provided the owners with considerable influence locally. In 1675, Niels Adeler advanced to the post of county governor, while one of his sons inherited the mayoralty. His business expansion led to substantial debt, but he managed to avoid bankruptcy. However, after his death in 1694, his business empire collapsed, leaving nothing to his many children. This chapter documents how two of his sons reacted to the loss of wealth and power with anger and violent attempts to bully the town bailiff into letting them keep their father’s properties. A sister, Anna Adeler Poulsen, married a merchant and stayed on. They built a trading house and became one of the 4–5 elite families who dominated the town. The Adeler Poulsen family lost its position when Anna’s grandsons sold the remaining properties after 1760.